Pancreatic ductal adenocarcinoma (PDAC) frequently presents with metastasis, but the
molecular programs in human PDAC cells that drive invasion are not well understood. Using …

Despite recent efforts to dissect the inter-tumor heterogeneity of pancreatic ductal
adenocarcinoma (PDAC) by determining prognosis-predictive gene expression signatures …

Pancreatic ductal adenocarcinoma (PDAC) is projected to be the second leading cause of
cancer mortality by 2030. Bulk transcriptomic analyses have distinguished 'classical'from …

Patient-derived pancreatic ductal adenocarcinoma (PDAC) organoid systems show great
promise for understanding the biological underpinnings of disease and advancing …

Intratumoral heterogeneity is a critical frontier in understanding how the tumor
microenvironment (TME) propels malignant progression. Here, we deconvolute the human …

Single-cell technologies have described heterogeneity across tissues, but the spatial
distribution and forces that drive single-cell phenotypes have not been well defined …

Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease refractory to all
targeted and immune therapies. However, our understanding of PDAC microenvironment …

Numerous cell states are known to comprise the pancreatic ductal adenocarcinoma (PDAC)
tumor microenvironment (TME). However, the developmental stemness and co-occurrence …

Purpose: Early detection of pancreatic ductal adenocarcinoma (PDAC) remains elusive.
Precursor lesions of PDAC, specifically intraductal papillary mucinous neoplasms (IPMNs) …

Pancreatic ductal adenocarcinoma has a poor clinical outcome and responses to
immunotherapy are suboptimal. Stromal fibroblasts are a dominant but heterogenous …